Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

NCT01381861 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Ovarian Cancer
Fallopian Tube Carcinoma
Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL: Carotuximab (TRC105)

Sponsor

Tracon Pharmaceuticals Inc.